Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Boehringer Ingelheim
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male and female patients with type 2 diabetes and with glomerular filtration rate (GFR) \<30 ml/min, who are not on chronic dialysis.
Insufficient glycemic control (hemoglobin A1c (HbA1c) between 7.0% and 10.0%)
Age 18 or over and not older than 80 years
You may not be if
Treatment with any other anti diabetic drug other than insulin and/or sulphonylurea within 3 months prior to informed consent
Myocardial infarction, stroke or transient ischemic attack (TIA) within 6 months prior to informed consent
Unstable or acute congestive heart failure
Clareo Health | Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive
